NM-101

Phase 1Small molecule

NNeuramedy Co. Ltd.

NM-101 is one of 7 small molecule programs targeting Single Ascending Dose. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Single Ascending DoseRecruiting

Single Ascending DosePhase 1

Recruiting

Competition

Competitive Landscape

12 competitors in Single Ascending Dose

#DrugCompanyPhaseTrials

JMT202

SShanghai JMT-Bio Inc.

Phase 1

1 2

DT-216P2

DDesign Therapeutics, Inc.

Phase 1

1 3

SYH2085

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 1

1 4

NM-101

NNeuramedy Co. Ltd.

Phase 1

1 5

HRS-4029

BBeijing Suncadia Pharmaceuticals Co., Ltd

Phase 1

1 6

Gensci142

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 1

1 7

WVE-006

WWave Life Sciences Ltd.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Tics1 trial

Single and Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of NM-101

Unknown status·NNeuramedy Co. Ltd.·Phase 1·NCT05790382·56 enrolled

Single Ascending Dose1 trial

Phase 1 Single Ascending Dose Study

Recruiting·NNeuramedy Co. Ltd.·Phase 1·NCT06934941·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for NM-101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NM-101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NM-101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Neuramedy Co. Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: NNeuramedy Co. Ltd.

NM-101

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Tics1 trial

Single Ascending Dose1 trial

References

Drug Info

Quick Facts

Related News